Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 01, 2015
- Source ID
- 10.1016/j.bbmt.2014.10.023
Entities
People
- Angela Dispenzieri
- Baldeep Wirk
- César O. Freytes
- Dan T. Vogl
- Daniel J. Landsburg
- Hillard M Lazarus
- Jennifer M. Bird
- Jiaxing Huang
- Manish Sharma
- Mei-jie Zhang
- Muneer H Abidi
- Parameswaran N. Hari
- Ravi Vij
- Reinhold Munker
- Robert A. Kyle
- Robert Peter Gale
- Shaji K Kumar
- Tamila L. Kindwall-keller
- Vivek Roy
- Xiaobo Zhong
Organizations
- ARIAD Pharmaceuticals
- Actinium Pharmaceuticals (United States)
- Amgen
- Blue Cross Blue Shield Association
- Celgene
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- GSK
- Incyte
- Kiadis Pharma (Netherlands)
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Osiris Therapeutics
- Otsuka (United States)
- Roche (United States)
- Sanofi-Aventis
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- St. Baldrick's Foundation
- StemCyte
- Swedish Orphan Biovitrum
- Tarix Orphan (United States)
- Terumo BCT (United States)
- University of Minnesota
- University of Utah